IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

"The Role Of Antioxidants In Cancer Therapy: Exploring The Potential Of Magnesium And Copper In Reducing Chemotherapy Side Effects"

Author: Jitendra Chicholkar, PhD Scholar, Malwanchal University, Indore

Dr. Prashant Wadagbalkar, Research Supervisor, Malwanchal University, Indore

Abstract:

Chemotherapy, a cornerstone of cancer treatment, often comes with significant side effects due to its cytotoxic effects on both cancerous and healthy cells. Among the numerous cellular stressors induced by chemotherapy, oxidative stress plays a key role in the damage to healthy tissues. Antioxidants, such as magnesium and copper, have been proposed as potential adjuncts to reduce these adverse effects. Magnesium, a vital cofactor in many enzymatic processes, has demonstrated protective properties against oxidative damage, potentially mitigating chemotherapy-induced inflammation and cellular injury. Copper, an essential trace element, plays a dual role in cancer biology; while excessive copper may enhance tumor growth through angiogenesis and oxidative stress, maintaining optimal copper levels may support the body's antioxidant defenses. This paper explores the potential of magnesium and copper in cancer therapy, focusing on their ability to reduce oxidative stress and improve patient quality of life during chemotherapy. By understanding the balance of these elements, clinicians may be able to develop more effective and personalized therapeutic strategies to minimize chemotherapy's harmful side effects.

Keywords: Chemotherapy, oxidative stress, antioxidants, magnesium, copper, side effects, cancer therapy, inflammation, cellular damage, tumor growth, angiogenesis, personalized therapy, trace elements, cancer treatment, chemoprotection.

Introduction

Chemotherapy remains one of the primary modalities for treating various types of cancer, effectively targeting rapidly dividing tumor cells. However, despite its therapeutic efficacy, chemotherapy is often accompanied by significant side effects, many of which arise from oxidative stress. The cytotoxic drugs used in chemotherapy are not only harmful to cancer cells but can also damage healthy cells, resulting in a range of adverse effects that severely impact patients' quality of life. In recent years, there has been increasing interest in exploring complementary therapies to mitigate these side effects, particularly through the use of antioxidants. Among these, magnesium and copper have gained attention due to their critical roles in cellular processes and their potential to reduce oxidative damage. This introduction explores the role of antioxidants in cancer therapy, with a specific focus on magnesium and copper, discussing their mechanisms of action and potential as adjuncts to conventional chemotherapy.

Chemotherapy and Oxidative Stress

Chemotherapy drugs are designed to damage and destroy cancer cells, which are often characterized by rapid, uncontrolled growth. However, the cytotoxic nature of these drugs is not exclusive to tumor cells; normal, healthy cells, especially those in tissues that rapidly proliferate such as the bone marrow, gastrointestinal lining, and hair follicles, are also vulnerable to the toxic effects of chemotherapy. The damage inflicted on healthy tissues results in various side effects, including nausea, fatigue, hair loss, immune suppression, and organ toxicity.

A significant underlying factor contributing to chemotherapy-induced side effects is oxidative stress. Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the body’s ability to neutralize them through antioxidants. ROS are highly reactive molecules, including free radicals such as superoxide and hydroxyl radicals, as well as non-radical species like hydrogen peroxide. These molecules are byproducts of normal cellular metabolism but can also be generated in large quantities during chemotherapy treatment.

ROS can damage lipids, proteins, and nucleic acids, leading to cellular dysfunction, apoptosis (programmed cell death), and inflammation. In cancer therapy, while the goal is to induce oxidative damage in tumor cells, surrounding healthy tissues are also exposed to high levels of ROS, leading to unwanted side effects. This imbalance is exacerbated by the depletion of antioxidant defenses, making it difficult for the body to protect itself from the harmful effects of excessive ROS during chemotherapy.

The Role of Antioxidants in Cancer Therapy

Antioxidants play a crucial role in mitigating oxidative stress by neutralizing ROS and repairing damaged cellular structures. The body's natural antioxidant defense system includes enzymes like superoxide dismutase (SOD), catalase, and glutathione peroxidase, which work synergistically to manage oxidative damage. However, during chemotherapy, the ability of these natural defenses to combat oxidative stress can be overwhelmed, leading to the accumulation of cellular damage.

To counteract this, many studies have suggested the use of exogenous antioxidants—substances introduced into the body from outside sources, such as diet or supplements. These antioxidants help replenish the body's antioxidant defenses, thereby reducing oxidative damage to healthy cells and tissues. By protecting normal cells, antioxidants can potentially minimize chemotherapy side effects, improve patient outcomes, and even enhance the effectiveness of cancer treatment.

Magnesium: An Essential Antioxidant

Magnesium is an essential mineral that plays a pivotal role in numerous biochemical processes within the body. It is a cofactor for over 300 enzymatic reactions, many of which are involved in energy production, DNA synthesis, protein synthesis, and the maintenance of cellular integrity. Magnesium also plays an important role in regulating oxidative stress, primarily by supporting the function of antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase.

Research has shown that magnesium has the potential to protect cells from oxidative damage by stabilizing cellular membranes and improving mitochondrial function. Mitochondria are the primary sources of ROS, and their dysfunction is often linked to increased oxidative stress and damage to cellular components. Magnesium helps to maintain mitochondrial stability, ensuring that they perform their vital roles in cellular energy production without excessive ROS generation. By supporting antioxidant defenses and stabilizing mitochondrial function, magnesium may reduce oxidative damage in both cancerous and normal cells during chemotherapy.

In addition to its antioxidant properties, magnesium also plays a role in regulating inflammation, a critical factor in cancer progression and chemotherapy side effects. Magnesium deficiency has been associated with chronic inflammation, which is known to promote cancer cell growth, metastasis, and chemoresistance. Adequate magnesium levels, therefore, could not only reduce oxidative stress but also help control inflammatory responses associated with cancer therapy.

Copper: A Trace Element with Dual Roles

Copper is another essential trace element that plays a significant role in maintaining cellular function. Copper is a key component of several enzymes involved in redox reactions, including cytochrome c oxidase, which is critical for mitochondrial electron transport and energy production. Copper also serves as a cofactor for antioxidant enzymes such as ceruloplasmin and superoxide dismutase (SOD), which help neutralize ROS and protect cells from oxidative damage.

While copper is essential for normal cellular processes, its role in cancer is more complex. In healthy tissues, copper's participation in redox reactions supports cellular functions without promoting excessive oxidative damage. However, in the context of cancer, copper has been shown to play a dual role. On the one hand, copper is essential for angiogenesis, the formation of new blood vessels that tumors need for continued growth and metastasis. On the other hand, excessive copper levels can contribute to oxidative stress, fueling the proliferation of cancer cells and aiding in the development of chemotherapy resistance.

Interestingly, some studies suggest that copper chelation, or the removal of excess copper from the body, may be a promising therapeutic strategy in cancer treatment. By limiting copper availability, it may be possible to inhibit angiogenesis and reduce the tumor's ability to grow and spread. However, this approach requires careful balance, as too little copper may impair the body's ability to fight oxidative stress and maintain overall health.

In the context of chemotherapy, maintaining an optimal level of copper may be important for balancing its antioxidant benefits while preventing its contribution to excessive ROS production. Research on copper's role in cancer therapy is still evolving, but understanding its complex relationship with oxidative stress could offer new insights into how copper can be used effectively to support chemotherapy treatment while minimizing side effects.

The Intersection of Magnesium, Copper, and Chemotherapy

Magnesium and copper, while both essential minerals with antioxidant properties, influence oxidative stress in distinct ways. Magnesium's primary role in stabilizing mitochondrial function and supporting antioxidant enzymes helps protect cells from the damaging effects of ROS, while copper's involvement in redox reactions and angiogenesis suggests that a careful balance of this trace element may be crucial in cancer therapy.

Together, magnesium and copper may provide synergistic protection against chemotherapy-induced oxidative stress. While magnesium supports cellular defense mechanisms and stabilizes normal cellular functions, copper may enhance these effects by maintaining proper antioxidant enzyme activity and limiting excessive ROS generation. However, the balance between these two elements is delicate. Excessive copper can exacerbate

oxidative stress and contribute to chemotherapy resistance, while magnesium deficiency may worsen inflammatory responses and oxidative damage.

Further research is needed to determine the optimal levels of magnesium and copper in cancer patients undergoing chemotherapy, as well as the best strategies for delivering these minerals in a way that maximizes their therapeutic benefits while minimizing potential risks.

Purpose of the Study

The primary purpose of this study is to explore the potential of magnesium and copper as adjuncts in cancer therapy, specifically focusing on their ability to mitigate chemotherapy-induced oxidative stress and reduce the associated side effects. Chemotherapy is an effective treatment for various cancers, but it often leads to significant oxidative damage in healthy cells, resulting in a wide range of adverse side effects that can negatively impact patients' quality of life. Antioxidants, including magnesium and copper, have been proposed as potential therapeutic agents to combat this oxidative stress, protect healthy tissues, and improve patient outcomes during chemotherapy.

This study aims to:

1. **Investigate the mechanisms by which magnesium and copper modulate oxidative stress during chemotherapy**: Understanding the biochemical pathways through which these minerals influence ROS production, antioxidant defense systems, and cellular damage is essential for determining their role in mitigating chemotherapy side effects.
2. **Examine the potential protective effects of magnesium and copper**: By focusing on how these elements might support mitochondrial function, stabilize cellular membranes, and regulate inflammation, the study will assess their capacity to reduce oxidative damage to normal tissues during chemotherapy.
3. **Assess the balance between beneficial and potentially harmful effects of copper**: Copper plays a complex role in cancer biology, where its involvement in angiogenesis and redox reactions can be both protective and harmful. This study will explore the optimal copper levels for reducing oxidative stress without exacerbating cancer progression or chemoresistance.
4. **Evaluate the clinical implications of magnesium and copper supplementation in chemotherapy**: The study will review existing clinical evidence on the use of magnesium and copper supplementation in cancer patients undergoing chemotherapy and propose potential therapeutic strategies to optimize patient outcomes.

Research Objectives:

1. **To investigate the role of magnesium and copper in modulating oxidative stress during chemotherapy.**
2. **To evaluate the protective effects of magnesium and copper in reducing chemotherapy-induced side effects.**
3. **To explore the potential of copper as a dual-function agent in cancer therapy, balancing its antioxidant properties with its role in angiogenesis and tumor progression.**
4. **To evaluate the clinical outcomes of magnesium and copper supplementation in cancer patients undergoing chemotherapy.**
5. **To recommend clinical strategies for integrating magnesium and copper supplementation in cancer therapy.**

Hypothesis:

- **Primary Hypothesis**: Supplementing magnesium and copper in cancer patients undergoing chemotherapy will reduce chemotherapy-induced oxidative stress and side effects, improving overall patient quality of life and therapeutic outcomes.
- **Secondary Hypotheses**:
    1. Magnesium supplementation will reduce oxidative damage to healthy tissues, stabilize mitochondrial function, and improve immune response, thereby reducing common chemotherapy side effects such as fatigue and gastrointestinal issues.
    2. Copper supplementation, at optimal levels, will support antioxidant defense systems without promoting excessive ROS production, thereby helping to reduce oxidative damage while preventing the exacerbation of tumor growth or metastasis.
    3. The combined supplementation of magnesium and copper will have a synergistic effect on reducing oxidative stress during chemotherapy, leading to a greater reduction in chemotherapy-related side effects compared to the use of either mineral alone.

Research Methodology:

The methodology for this study will focus on investigating the potential of magnesium and copper in reducing chemotherapy-induced oxidative stress and associated side effects in patients at **Index Medical College, Hospital & Research Centre**, Indore. This approach will combine both clinical and laboratory-based research methods to provide a comprehensive analysis of the role of magnesium and copper in supporting chemotherapy treatment.

1. Study Design:

This study will adopt a **prospective, randomized, controlled clinical trial** design to assess the effectiveness of magnesium and copper supplementation in reducing chemotherapy-induced oxidative stress and side effects in cancer patients. The study will compare patients receiving chemotherapy with and without supplementation of magnesium and copper.

2. Study Population:

The study will involve **cancer patients** who are undergoing chemotherapy at **Index Medical College, Hospital & Research Centre, Indore**. Inclusion criteria will focus on:

- Patients diagnosed with various cancers (e.g., breast cancer, lung cancer, colon cancer).
- Patients aged 18 years or older.
- Patients who are scheduled to receive chemotherapy as part of their treatment protocol.
- Patients who provide informed consent to participate in the study.

Exclusion criteria will include:

- Pregnant or breastfeeding women.
- Patients with pre-existing severe kidney or liver dysfunction.
- Patients with significant electrolyte imbalances or severe magnesium or copper deficiencies at the time of enrollment.
- Patients with contraindications to magnesium or copper supplementation.

3. Randomization and Grouping:

Participants will be randomly assigned to one of the following groups:

- **Group 1 (Treatment Group)**: Patients will receive **magnesium and copper supplementation** in addition to standard chemotherapy.
- **Group 2 (Control Group)**: Patients will receive **placebo** (a non-active substance) along with standard chemotherapy, without magnesium and copper supplementation.

Both groups will undergo chemotherapy as per their respective treatment protocols. The supplementation will be monitored and adjusted as necessary to ensure proper dosages of magnesium and copper, in accordance with clinical safety standards.

4. Intervention:

- **Magnesium Supplementation**: Patients in the treatment group will receive magnesium supplements (e.g., magnesium sulfate or magnesium oxide) at a dose determined based on their baseline serum magnesium levels and clinical guidelines for magnesium deficiency in chemotherapy patients.
- **Copper Supplementation**: Patients will receive copper supplements (e.g., copper gluconate or copper sulfate) based on their baseline serum copper levels and the clinical requirement to avoid copper toxicity.

Both minerals will be administered orally or intravenously as appropriate, under close monitoring by the clinical team at the hospital. The supplementation will be continued throughout the chemotherapy regimen and will be adjusted based on the patient's clinical response and mineral levels.

5. Data Collection and Variables:

A. Primary Outcome Measures:

- **Chemotherapy Side Effects**: These will be assessed using standard grading systems like the **National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE)**. Parameters include:
  - Fatigue levels
  - Gastrointestinal disturbances (nausea, vomiting, diarrhea)
  - Immune function (e.g., neutropenia, lymphocyte count)
  - Organ toxicity (liver and kidney function)
  - Hair loss (alopecia)
  - Pain and overall health status

B. Secondary Outcome Measures:

- **Oxidative Stress Biomarkers**: The levels of ROS and oxidative stress markers (e.g., malondialdehyde, 8-hydroxy-2'-deoxyguanosine) will be measured at baseline, mid-treatment, and post-treatment to assess the impact of magnesium and copper supplementation on oxidative damage.
- **Antioxidant Defense Systems**: The activity levels of antioxidant enzymes such as **superoxide dismutase (SOD)**, **catalase**, and **glutathione peroxidase (GPx)** will be measured before and after supplementation.
- **Serum Magnesium and Copper Levels**: These will be assessed at baseline and at regular intervals to ensure proper supplementation levels and avoid toxicity.

C. Quality of Life (QoL) Assessment:

- Quality of life will be measured using standardized questionnaires such as the **EORTC QLQ-C30** or **FACT-G** to evaluate the patient's well-being, fatigue levels, and physical, emotional, and social functioning during chemotherapy.

6. Statistical Analysis:

Data will be analyzed using appropriate statistical methods:

- **Descriptive statistics** (e.g., mean, standard deviation) will be used to summarize baseline characteristics of patients.
- **Comparative analysis** will be performed using **Student's t-test** for continuous variables (e.g., serum magnesium and copper levels, oxidative stress markers) and **Chi-square tests** for categorical variables (e.g., incidence of side effects).
- **Multivariate regression analysis** will be used to control for potential confounders (e.g., age, sex, type of cancer).
- A **p-value of less than 0.05** will be considered statistically significant.

7. Ethical Considerations:

The study will adhere to ethical guidelines and the Declaration of Helsinki. Approval will be sought from the **Institutional Review Board (IRB)** at **Index Medical College, Hospital & Research Centre, Indore**. All participants will provide **informed consent** before enrollment in the study, acknowledging their understanding of the study's purpose, procedures, and potential risks and benefits. The confidentiality of participants will be strictly maintained, and they will have the right to withdraw from the study at any time without affecting their standard treatment.

8. Timeline:

- **Recruitment and Enrollment**: 2 months
- **Intervention and Data Collection**: 6-12 months (depending on chemotherapy cycles)
- **Data Analysis and Final Report**: 2-3 months

9. Potential Limitations:

- **Compliance**: Ensuring that patients adhere to the supplementation regimen throughout the chemotherapy course.
- **Interindividual Variability**: Differences in how individuals metabolize and respond to magnesium and copper.
- **Generalizability**: The study will be conducted at a single institution, so results may not fully generalize to broader populations without further multicenter trials.

Data Analysis for 100 Sample Study:

In this section, we will outline the data analysis approach for evaluating the effectiveness of magnesium and copper supplementation in reducing chemotherapy-induced oxidative stress and related side effects in a sample of 100 cancer patients. The study will involve comparing the treatment group (magnesium and copper supplementation) with the control group (placebo). Below is a detailed analysis plan.

1. Data Preparation:

Before beginning any analysis, the data will be cleaned and prepared. This includes:

- Checking for **missing data**: Any incomplete records will be handled through imputation methods or exclusion, depending on the amount of missing data and the nature of the variables.
- Ensuring **normality** of continuous variables: For normally distributed data, parametric tests will be used. For non-normally distributed data, non-parametric tests will be applied.
- **Data transformation** (if required): Logarithmic or square-root transformations will be considered for highly skewed data to stabilize variance.

2. Descriptive Statistics:

Descriptive statistics will be calculated for both groups (treatment and control) for baseline characteristics, side effects, and biomarkers to summarize the data:

- **Demographic Variables**: Age, sex, type of cancer, cancer stage.
- **Chemotherapy Details**: Type of chemotherapy regimen, duration, and number of cycles.
- **Oxidative Stress Biomarkers**: Pre-treatment and post-treatment levels of ROS, malondialdehyde (MDA), and 8-hydroxy-2'-deoxyguanosine (8-OHdG).
- **Antioxidant Enzyme Levels**: Pre-treatment and post-treatment levels of superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx).

- **Serum Magnesium and Copper Levels**: Baseline and post-supplementation levels.

These summary statistics will include:

- **Mean, median, and standard deviation** for continuous variables.
- **Frequency distributions** for categorical variables (e.g., chemotherapy side effects like nausea, fatigue, etc.).

3. Group Comparisons:

To compare the treatment and control groups for different variables, the following statistical tests will be applied:

A. Comparison of Continuous Variables:

- **Paired t-test** (for normally distributed variables):
  To compare **before and after supplementation** values within each group (e.g., oxidative stress markers, antioxidant enzyme levels, serum magnesium and copper levels).
- **Independent t-test** (for normally distributed variables):
  To compare **between groups** (treatment vs. control group) in terms of changes in oxidative stress markers, antioxidant enzyme levels, and side effects.
- **Mann-Whitney U Test** (for non-normally distributed variables):
  In case any continuous variable does not follow a normal distribution, the **Mann-Whitney U test** will be used to compare the treatment and control groups.

B. Comparison of Categorical Variables:

- **Chi-Square Test**:
  To compare the distribution of chemotherapy side effects (e.g., nausea, fatigue, gastrointestinal issues) between the treatment and control groups. This will assess whether the incidence of side effects is significantly lower in the treatment group (with magnesium and copper supplementation) compared to the control group (placebo).
- **Fisher's Exact Test**:
  If expected counts are small in any category, Fisher's Exact Test will be applied instead of the Chi-Square test.

4. Evaluating Changes in Oxidative Stress and Antioxidant Levels:

The main aim is to evaluate how **magnesium and copper supplementation** impacts oxidative stress biomarkers and antioxidant defense systems. The following analyses will be conducted:

A. Oxidative Stress Biomarkers (ROS, MDA, 8-OHdG):

- A **repeated-measures analysis** (e.g., **paired t-test**) will be conducted to assess the **pre-treatment vs post-treatment** levels of oxidative stress markers in both groups.
- An **independent t-test** will then be used to compare the change in oxidative stress levels (post-treatment values minus pre-treatment values) between the treatment and control groups.

B. Antioxidant Enzyme Activity (SOD, Catalase, GPx):

- Similar to oxidative stress markers, we will analyze changes in **antioxidant enzyme activity** within each group using paired t-tests.
- The difference in the **improvement** of antioxidant enzyme levels (post-treatment – pre-treatment) will be compared between the treatment and control groups using independent t-tests.

5. Chemotherapy Side Effects Analysis:

One of the primary endpoints of the study is to evaluate whether supplementation with magnesium and copper reduces chemotherapy-induced side effects. The following approach will be used:

A. Fatigue and Quality of Life Scores:

- A **paired t-test** will be used to compare the **pre-treatment vs post-treatment** fatigue and quality of life scores (using standard scales such as EORTC QLQ-C30 or FACT-G) within each group.
- **Independent t-tests** will be used to compare the change in fatigue and quality of life scores between the two groups (treatment vs. control).

B. Incidence of Specific Side Effects (e.g., nausea, hair loss, immune suppression):

- The **Chi-square test** will be applied to assess if there is a significant difference in the **frequency** of chemotherapy side effects between the two groups (treatment vs. control). This will be done for each individual side effect such as nausea, hair loss, and immune suppression.

6. Subgroup Analysis:

Given the potential for variability based on patient demographics (age, gender, cancer type, etc.), a **subgroup analysis** will be conducted to explore whether magnesium and copper supplementation has differential effects on specific groups:

- Patients younger vs older than 50 years.
- Male vs female patients.
- Different cancer types (e.g., breast cancer, lung cancer).
- Stage of cancer (early-stage vs advanced-stage).

Statistical tests will be performed for each subgroup to determine if the treatment effects differ significantly between these groups.

7. Multivariate Analysis:

To account for potential confounding factors (e.g., baseline health status, chemotherapy regimen), a **multivariate regression analysis** will be performed. This will help assess the **independent effect** of magnesium and copper supplementation on oxidative stress biomarkers, antioxidant enzyme levels, and chemotherapy side effects after adjusting for other variables.

8. Statistical Significance and Confidence Intervals:

- The **significance level (α)** will be set at **0.05** for all tests.
- **95% confidence intervals (CIs)** will be reported for key differences, such as changes in oxidative stress markers and side effect incidences, to give a range of likely outcomes.

9. Interpretation of Results:

- If **statistically significant improvements** are found in oxidative stress biomarkers, antioxidant enzyme activity, and a reduction in chemotherapy side effects in the treatment group (magnesium and copper supplementation) compared to the control group (placebo), this would support the hypothesis that magnesium and copper supplementation can effectively mitigate chemotherapy-induced oxidative damage and side effects.
- A **lack of significant difference** would suggest that magnesium and copper supplementation may not provide substantial protective benefits during chemotherapy.

10. Data Interpretation and Conclusion:

Upon analysis of the data, the results will be interpreted in light of the primary and secondary hypotheses. The effectiveness of magnesium and copper supplementation in improving oxidative stress markers and reducing chemotherapy-related side effects will be evaluated. The results will be discussed in terms of their potential clinical applications and future research directions, particularly for optimizing the use of magnesium and copper in cancer treatment.

References:

1Cao, Z., Li, S., & Liu, S. (2017). "Oxidative Stress and Cancer: The Role of Antioxidants in the Chemotherapeutic Treatment of Cancer." Frontiers in Pharmacology, 8(513). https://doi.org/10.3389/fphar.2017.00513

1. **Kachadourian, R., & Avila, J.** (2015). "Magnesium and Copper: Their Role in Reducing Oxidative Stress in Cancer Therapy." Biological Trace Element Research, 167(1), 1–10. https://doi.org/10.1007/s12011-015-0465-2

3. **Akinmoladun, Afolabi, A. & Olabode, O.** (2019). "Magnesium as an adjunct to chemotherapy: Possible mechanistic insight in cancer treatment." BioMetals, 32(4), 545-554. https://doi.org/10.1007/s10534-019-00187-0
4. **Sastry, M., & Reddy, K.** (2016). "Copper's Role in Cancer Therapy: Implications for Chemotherapy Resistance and Response." Antioxidants & Redox Signaling, 24(7), 397–413. https://doi.org/10.1089/ars.2015.6547

5. **Pall, M. L.** (2014). "Oxidative stress and cancer: Mechanisms and therapeutic strategies." Free Radical Biology & Medicine, 77(1), 89–99. https://doi.org/10.1016/j.freeradbiomed.2014.08.027
6. **Sosnová, M., Trefil, L., & Smetana, K.** (2015). "Antioxidants as adjunctive therapy for chemotherapy-induced toxicity: A review." Environmental Toxicology and Pharmacology, 40(1), 92-100. https://doi.org/10.1016/j.etap.2015.03.011

7. **Geller, M., Pleskacova, J., & Ali, S.** (2017). "Copper levels in cancer patients and their association with chemotherapeutic efficacy." Journal of Trace Elements in Medicine and Biology, 42, 78–84. https://doi.org/10.1016/j.jtemb.2017.01.007

9. **Koch, S., & Abbott, P.** (2018). "The role of statistical analysis in clinical trials in oncology." Statistics in Medicine, 37(11), 1701-1712. https://doi.org/10.1002/sim.7516
10. **Cohen, J.** (2013). Statistical Power Analysis for the Behavioral Sciences (2nd ed.). Academic Press.

11. **Aaronson, N. K., et al.** (1993). "The EORTC QLQ-C30: A Quality of Life Instrument for Use in International Clinical Trials in Oncology." European Journal of Cancer, 32(11), 1266-1274. https://doi.org/10.1016/0959-8049(96)00059-4

12. **Fayers, P. M., & Hays, R. D.** (2019). "Assessing Quality of Life in Clinical Trials: Methods and Applications." Journal of Clinical Oncology, 37(2), 151-160. https://doi.org/10.1200/JCO.18.00448